These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 12642693)

  • 1. Coadministration of UCN-01 with MEK1/2 inhibitors potently induces apoptosis in BCR/ABL+ leukemia cells sensitive and resistant to ST1571.
    Yu C; Dai Y; Dent P; Grant S
    Cancer Biol Ther; 2002; 1(6):674-82. PubMed ID: 12642693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells.
    Yu C; Krystal G; Varticovksi L; McKinstry R; Rahmani M; Dent P; Grant S
    Cancer Res; 2002 Jan; 62(1):188-99. PubMed ID: 11782377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological inhibitors of the mitogen-activated protein kinase (MAPK) kinase/MAPK cascade interact synergistically with UCN-01 to induce mitochondrial dysfunction and apoptosis in human leukemia cells.
    Dai Y; Yu C; Singh V; Tang L; Wang Z; McInistry R; Dent P; Grant S
    Cancer Res; 2001 Jul; 61(13):5106-15. PubMed ID: 11431348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined treatment with the checkpoint abrogator UCN-01 and MEK1/2 inhibitors potently induces apoptosis in drug-sensitive and -resistant myeloma cells through an IL-6-independent mechanism.
    Dai Y; Landowski TH; Rosen ST; Dent P; Grant S
    Blood; 2002 Nov; 100(9):3333-43. PubMed ID: 12384435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr/Abl+ human myeloid leukemia cells.
    Yu C; Rahmani M; Almenara J; Subler M; Krystal G; Conrad D; Varticovski L; Dent P; Grant S
    Cancer Res; 2003 May; 63(9):2118-26. PubMed ID: 12727828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of apoptosis in BCR/ABL+ cells by histone deacetylase inhibitors involves reciprocal effects on the RAF/MEK/ERK and JNK pathways.
    Yu C; Subler M; Rahmani M; Reese E; Krystal G; Conrad D; Dent P; Grant S
    Cancer Biol Ther; 2003; 2(5):544-51. PubMed ID: 14614324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic interactions between MEK1/2 and histone deacetylase inhibitors in BCR/ABL+ human leukemia cells.
    Yu C; Dasmahapatra G; Dent P; Grant S
    Leukemia; 2005 Sep; 19(9):1579-89. PubMed ID: 16015388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Flavopiridol potentiates STI571-induced mitochondrial damage and apoptosis in BCR-ABL-positive human leukemia cells.
    Yu C; Krystal G; Dent P; Grant S
    Clin Cancer Res; 2002 Sep; 8(9):2976-84. PubMed ID: 12231544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapamycin and UCN-01 synergistically induce apoptosis in human leukemia cells through a process that is regulated by the Raf-1/MEK/ERK, Akt, and JNK signal transduction pathways.
    Hahn M; Li W; Yu C; Rahmani M; Dent P; Grant S
    Mol Cancer Ther; 2005 Mar; 4(3):457-70. PubMed ID: 15767555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825.
    Nguyen TK; Rahmani M; Harada H; Dent P; Grant S
    Blood; 2007 May; 109(9):4006-15. PubMed ID: 17218385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571.
    Yu C; Rahmani M; Conrad D; Subler M; Dent P; Grant S
    Blood; 2003 Nov; 102(10):3765-74. PubMed ID: 12893773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.
    Nguyen TK; Rahmani M; Gao N; Kramer L; Corbin AS; Druker BJ; Dent P; Grant S
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2239-47. PubMed ID: 16609040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Farnesyltransferase inhibitors interact synergistically with the Chk1 inhibitor UCN-01 to induce apoptosis in human leukemia cells through interruption of both Akt and MEK/ERK pathways and activation of SEK1/JNK.
    Dai Y; Rahmani M; Pei XY; Khanna P; Han SI; Mitchell C; Dent P; Grant S
    Blood; 2005 Feb; 105(4):1706-16. PubMed ID: 15494423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2.
    Dai Y; Rahmani M; Corey SJ; Dent P; Grant S
    J Biol Chem; 2004 Aug; 279(33):34227-39. PubMed ID: 15175350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The tyrosine kinase inhibitor CGP 57148 (ST1 571) induces apoptosis in BCR-ABL-positive cells by down-regulating BCL-X.
    Oetzel C; Jonuleit T; Götz A; van der Kuip H; Michels H; Duyster J; Hallek M; Aulitzky WE
    Clin Cancer Res; 2000 May; 6(5):1958-68. PubMed ID: 10815921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitors of MEK1/2 interact with UCN-01 to induce apoptosis and reduce colony formation in mammary and prostate carcinoma cells.
    McKinstry R; Qiao L; Yacoub A; Dai Y; Decker R; Holt S; Hagan MP; Grant S; Dent P
    Cancer Biol Ther; 2002; 1(3):243-53. PubMed ID: 12432271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cotreatment with suberanoylanilide hydroxamic acid and 17-allylamino 17-demethoxygeldanamycin synergistically induces apoptosis in Bcr-Abl+ Cells sensitive and resistant to STI571 (imatinib mesylate) in association with down-regulation of Bcr-Abl, abrogation of signal transducer and activator of transcription 5 activity, and Bax conformational change.
    Rahmani M; Reese E; Dai Y; Bauer C; Kramer LB; Huang M; Jove R; Dent P; Grant S
    Mol Pharmacol; 2005 Apr; 67(4):1166-76. PubMed ID: 15625278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beyond directed therapeutics--are two drugs always better than one?
    Carroll M
    Cancer Biol Ther; 2002; 1(6):683-4. PubMed ID: 12642694
    [No Abstract]   [Full Text] [Related]  

  • 19. Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms.
    Dai Y; Rahmani M; Pei XY; Dent P; Grant S
    Blood; 2004 Jul; 104(2):509-18. PubMed ID: 15039284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergism between bosutinib (SKI-606) and the Chk1 inhibitor (PF-00477736) in highly imatinib-resistant BCR/ABL⁺ leukemia cells.
    Nguyen T; Hawkins E; Kolluri A; Kmieciak M; Park H; Lin H; Grant S
    Leuk Res; 2015 Jan; 39(1):65-71. PubMed ID: 25465126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.